Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson's disease
- PMID: 38040775
- PMCID: PMC10692157
- DOI: 10.1038/s41598-023-48188-0
Imbalanced motivated behaviors according to motor sign asymmetry in drug-naïve Parkinson's disease
Abstract
Few studies have considered the influence of motor sign asymmetry on motivated behaviors in de novo drug-naïve Parkinson's disease (PD). We tested whether motor sign asymmetry could be associated with different motivated behavior patterns in de novo drug-naïve PD. We performed a cross-sectional study in 128 de novo drug-naïve PD patients and used the Ardouin Scale of Behavior in Parkinson's disease (ASBPD) to assess a set of motivated behaviors. We assessed motor asymmetry based on (i) side of motor onset and (ii) MDS-UPDRS motor score, then we compared right hemibody Parkinson's disease to left hemibody Parkinson's disease. According to the MDS-UPDRS motor score, patients with de novo right hemibody PD had significantly lower frequency of approach behaviors (p = 0.031), including nocturnal hyperactivity (p = 0.040), eating behavior (p = 0.040), creativity (p = 0.040), and excess of motivation (p = 0.017) than patients with de novo left hemibody PD. Patients with de novo left hemibody PD did not significantly differ from those with de novo right hemibody PD regarding avoidance behaviors including apathy, anxiety and depression. Our findings suggest that motor sign asymmetry may be associated with an imbalance between motivated behaviors in de novo drug-naïve Parkinson's disease.
© 2023. The Author(s).
Conflict of interest statement
Dr. Béreau reports reimbursement of travel expenses to scientific meetings from ELIVIE, Medtronic and Boston Scientific, honoraria from Merz Pharma and Allergan for lecturing outside the submitted work. Dr. Castrioto reports research grants from France Parkinson Foundation and Medtronic, honoraria from ELIVIE for lecturing outside the submitted work. Dr. Wirth reports research grant from the French Society of Neurology, the APTES and the Fondation Planiol organizations and travels reimbursement from LVL medical outside the submitted work. Dr. Fraix reports reimbursement of travel expenses from Merz, AbbVie, honoraria for scientific counselling from AbbVie outside the submitted work. Dr. Azulay reports honoraria for consultancies and advisory boards from Abbvie, Merz, Allergan, Medtronic, Ever Pharma outside the submitted work. Dr. Moro reports honorarium from Medtronic and Newronica for lecturing, and an educational grant from Boston outside the submitted work. Dr. Thobois reports grants from France Parkinson, FRM, ANR, PHRC, UCB, Neurodis, personal fees from Aguettant, Boston Scientific, Novartis, non-financial support from Zambon, Abbvie, Elivie outside the submitted work. Dr. Tranchant reports reimbursement of travel expenses from Merz, and honoraria from Allergan for lecturing outside the submitted work. Dr. Krack reports a research grant from UCB for the present study, research grants from Swiss National Science Foundation, ROGER DE SPOELBERCH Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Boston Scientific, and Aleva, lecturing fees paid to employing institution (Inselspital) from Boston Scientific, as well as reimbursement of travelling expenses to scientific meeting by Zambon outside the submitted work. Dr. Anheim reports travel grants and/or honoraria from Actelion Pharmaceuticals, Johnson and Johnson, Teva, LVL, Aguettant, Orkyn, AbbVie and Merz outside the submitted work. Mathieu Servant, Eugénie Lhommée, Maxime Desmarets, Amélie Bichon, Pierre Pélissier, Emmanuelle Schmitt, Hélène Klinger, Nadine Longato, Clélie Phillipps, Isabelle Benatru, Frank Durif, Emmanuel Broussolle declare no competing interest.
Figures
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
